In Good Company with Nicolai Tangen
HIGHLIGHTS: David Ricks - CEO of Eli Lilly
Feb 21, 2025
David Ricks, Chair and CEO of Eli Lilly, discusses the groundbreaking advances in weight-reducing drugs that extend their benefits beyond initial intentions, like treating addiction and Alzheimer's. He highlights how Eli Lilly has halved drug development timelines through innovative approaches and AI. Ricks also navigates the challenges of drug pricing ethics in different markets, emphasizing the balance between patient access and business sustainability. This conversation reveals the exciting future of medicine and its transformative potential.
10:31
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Eli Lilly's development of GLP-1 drugs illustrates a pivotal shift in weight management, transitioning from side effects to targeted treatments for obesity and related diseases.
- The pharmaceutical industry grapples with ethical dilemmas in drug pricing, balancing patient access with the financial sustainability of innovative drug development.
Deep dives
Revolutionizing Weight Management
Recent advancements in GLP-1 drugs are transforming the approach to weight management and various chronic diseases. Initially, weight loss was an unintended side effect of these medications, but drugs like Trisepatide have now been specifically designed to target weight reduction while also addressing conditions such as diabetes. By stimulating gut hormones, these medications help regulate appetite and manage significant health issues associated with obesity, including cardiovascular and kidney diseases. As the industry moves forward, effective management of weight could shift from being viewed as a burden to a more manageable choice for individuals.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
